Thursday, November 3, 2011
Box 1. Incubators no more.
In 2007, Pfizer Inc. and Biogen Idec Inc. created incubators that
provided both space and funding for startups.
Idec Innovation Incubator funded and housed two companies: Escoublac Inc. and Provasculon Inc.
Idec spokesperson Naomi Aoki said the incubator is now closed and that the
company is "continuing to rethink its incubator strategy." Escoublac
was developing osteocalcin technology from Columbia University.
The biotech shut down in the fall of 2010, and Columbia repartnered the
technology with Sanofi earlier this year.1
company Provasculon is still being supported by Biogen but is no longer in the
physical incubator. "We are still working to help to meet their business
goals and business plan. They are a cardiovascular-focused company, which is
not a strategic area we are focused on," said Aoki.
Incubator in La Jolla supported three companies: Wintherix LLC, Fabrus LLC and RGo BioScience LLC. Wintherix and Fabrus
left the incubator without granting Pfizer rights to any programs, although
Pfizer retains equity in the companies. A Pfizer spokesperson confirmed to SciBX that RGo BioScience has been
acquired by Pfizer and that the incubator space has been up for sale since
is developing activators of the wingless-type MMTV integration site (WNT)
signaling pathway to promote bone growth.2 The biotech has since
spun out a related company, Epitherix, which is developing WNT inhibitors for
cancer.3 Fabrus, which is building libraries for antibody discovery,4
has funding from Opko Health Inc. -CC